凯立新材(688269) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was CNY 494,523,598.30, representing a year-on-year increase of 57.61%[2] - The net profit attributable to shareholders decreased by 25.77% to CNY 41,259,946.58 compared to the same period last year[2] - The net profit for Q1 2023 was CNY 41,259,946.58, a decrease of 25.8% compared to CNY 55,584,727.42 in Q1 2022[13] - The net profit for Q1 2023 was CNY 38.20 million, down 30.7% from CNY 55.19 million in Q1 2022[25] - The total revenue from operating activities was CNY 275,658,026.08, up from CNY 229,521,513.95 in the same period last year, representing a growth of 20.1%[16] - The company reported a total comprehensive income of CNY 40,854,418.90 for Q1 2023, down from CNY 55,414,167.39 in Q1 2022, reflecting a decline of 26.4%[14] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.32, compared to CNY 0.43 in Q1 2022, indicating a decrease of 25.6%[14] Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -112,997,488.09, a significant decline of 2,906.47% year-on-year[2] - The cash flow from operating activities showed a net outflow of CNY 112,997,488.09, compared to a net inflow of CNY 4,026,322.32 in Q1 2022[17] - The cash flow from operating activities showed a net outflow of CNY 180.16 million, compared to a net outflow of CNY 7.79 million in Q1 2022[27] - The company's cash and cash equivalents decreased to RMB 301,292,707.00 from RMB 460,316,208.73 as of December 31, 2022, representing a decline of 34.6%[9] - The cash and cash equivalents at the end of Q1 2023 were CNY 300,962,707.00, down from CNY 374,384,787.32 at the end of Q1 2022[18] - The net increase in cash and cash equivalents was -$197,827,009.22, indicating a significant cash outflow[28] - The initial cash and cash equivalents balance was $420,379,880.64, showing a decline in liquidity[28] - The impact of exchange rate changes on cash and cash equivalents was -$4,728.15, reflecting currency fluctuations[28] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,530,057,133.64, a slight increase of 0.05% from the end of the previous year[3] - The total assets amounted to CNY 1,418.28 million, slightly down from CNY 1,420.84 million in the previous quarter[22] - The company's total liabilities decreased to RMB 519,359,629.12 from RMB 559,373,956.00, a reduction of 7.1%[11] - The total liabilities decreased to CNY 430.17 million from CNY 470.52 million in the previous quarter, indicating a reduction of 8.6%[22] - The total liabilities as of March 31, 2023, were CNY 1,035,399,196.30, a slight decrease from CNY 1,058,414,311.33 at the end of 2022[20] Research and Development - Research and development expenses totaled CNY 13,542,325.31, accounting for 2.74% of operating revenue, a decrease of 0.91 percentage points year-on-year[3] - Research and development expenses for Q1 2023 were RMB 13,542,325.31, up from RMB 11,460,520.14 in Q1 2022, reflecting a growth of 18.2%[12] - Research and development expenses increased to CNY 13.54 million, up from CNY 11.46 million in the same period last year, reflecting a growth of 18.2%[24] Market and Growth Strategy - The company reported a significant increase in multi-phase product revenue, which rose by 48.20% year-on-year, while the revenue from pharmaceutical and chemical new materials grew by 46.29% and 123.01%, respectively[5] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[5] Profitability - The weighted average return on equity was 4.17%, down by 2.22 percentage points compared to the previous year[3] - The gross profit margin for catalyst products decreased due to a higher proportion of lower-margin sales, impacting overall profitability[5]